Zogenix Stock Price, News & Analysis (NASDAQ:ZGNX)

$41.25 -0.10 (-0.24 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$41.25
Today's Range$40.65 - $42.45
52-Week Range$8.50 - $43.35
Volume823,758 shs
Average Volume598,462 shs
Market Capitalization$1.42 billion
P/E Ratio-9.33
Dividend YieldN/A
Beta1.79

About Zogenix (NASDAQ:ZGNX)

Zogenix logoZogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Medical Devices
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Debt-to-Equity Ratio0.23%
Current Ratio2.71%
Quick Ratio2.71%

Price-To-Earnings

Trailing P/E Ratio-9.33257918552036
Forward P/E Ratio-9.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$28.85 million
Price / Sales48.97
Cash FlowN/A
Price / CashN/A
Book Value$4.87 per share
Price / Book8.47

Profitability

Trailing EPS($4.42)
Net Income$-69,700,000.00
Net Margins-309.76%
Return on Equity-99.61%
Return on Assets-44.17%

Miscellaneous

Employees67
Outstanding Shares34,250,000

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Tuesday, August, 8th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. The company had revenue of $7.10 million for the quarter, compared to analysts' expectations of $3.48 million. Zogenix had a negative return on equity of 99.61% and a negative net margin of 309.76%. The firm's quarterly revenue was up 238.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.76) EPS. View Zogenix's Earnings History.

Where is Zogenix's stock going? Where will Zogenix's stock price be in 2018?

6 equities research analysts have issued 1-year price targets for Zogenix's shares. Their predictions range from $28.00 to $56.00. On average, they expect Zogenix's share price to reach $48.00 in the next twelve months. View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:

  • 1. Mizuho analysts commented, "We are encouraged by the company’s execution as well as solid clinical data from ZX008 in the previous Study 1 and see a high likelihood that the upcoming top- line data readouts will be favorable. We believe the readout is likely to take place in June 2018." (2/1/2018)
  • 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (1/27/2018)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:

  • Cam L. Garner, Independent Chairman of the Board (Age 67)
  • Stephen J. Farr Ph.D., President, Chief Executive Officer, Director (Age 56)
  • Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary (Age 48)
  • Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer (Age 51)
  • Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer (Age 53)
  • James B. Breitmeyer M.D., Ph.D., Director (Age 61)
  • Roger L. Hawley, Director (Age 63)
  • Erle T. Mast, Independent Director (Age 52)
  • Mark C. Wiggins, Independent Director (Age 59)

Who owns Zogenix stock?

Zogenix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (11.59%), BlackRock Inc. (7.76%), Goldman Sachs Group Inc. (3.54%), Deutsche Bank AG (3.03%), Eagle Asset Management Inc. (2.90%) and VHCP Management II LLC (2.49%). Company insiders that own Zogenix stock include Bradley S Galer, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Who sold Zogenix stock? Who is selling Zogenix stock?

Zogenix's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ascend Capital LLC, Candriam Luxembourg S.C.A., Emory University, Gagnon Securities LLC, VHCP Management II LLC, EAM Investors LLC and Jane Street Group LLC. View Insider Buying and Selling for Zogenix.

Who bought Zogenix stock? Who is buying Zogenix stock?

Zogenix's stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., Farallon Capital Management LLC, Deutsche Bank AG, Broadfin Capital LLC, Perceptive Advisors LLC and Goldman Sachs Group Inc.. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy Zogenix stock?

Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of Zogenix stock can currently be purchased for approximately $41.25.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.42 billion and generates $28.85 million in revenue each year. The company earns $-69,700,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis. Zogenix employs 67 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 HORTON STREET #455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (ZGNX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zogenix (NASDAQ:ZGNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.00$48.00$46.00$24.75
Price Target Upside: 32.05% upside40.76% upside21.69% upside67.80% upside

Zogenix (NASDAQ:ZGNX) Consensus Price Target History

Price Target History for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ:ZGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018MizuhoReiterated RatingBuy$51.00HighView Rating Details
11/27/2017JMP SecuritiesInitiated CoverageOutperform$56.00MediumView Rating Details
10/2/2017Leerink SwannReiterated RatingOutperform -> Outperform$20.00 -> $50.00HighView Rating Details
9/29/2017Stifel NicolausReiterated RatingBuy$26.00 -> $55.00N/AView Rating Details
9/29/2017William BlairUpgradeMarket Perform -> OutperformN/AView Rating Details
3/11/2017AegisReiterated RatingBuy$28.00N/AView Rating Details
9/21/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Zogenix (NASDAQ:ZGNX) Earnings History and Estimates Chart

Earnings by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ ZGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.95)($1.11)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.90)$3.48 million$7.10 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.88)($0.85)$4.23 million$2.70 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.84)($0.73)$5.05 million$10.99 millionViewN/AView Earnings Details
11/7/2016Q3($0.96)($0.69)$3.10 million$6.57 millionViewListenView Earnings Details
8/9/2016Q216($0.81)($0.76)$5.36 million$2.10 millionViewN/AView Earnings Details
5/10/2016Q116($0.62)($0.42)$4.90 million$9.20 millionViewListenView Earnings Details
3/10/2016Q415($0.69)($0.36)$6.39 million$6.10 millionViewListenView Earnings Details
11/9/2015Q315($0.74)($0.65)$5.90 million$9.12 millionViewN/AView Earnings Details
8/10/2015Q215($0.77)$3.78$5.13 million$7.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.15)$8.54 million$4.60 millionViewListenView Earnings Details
3/10/2015Q414($0.11)($0.13)$11.50 million$14.90 millionViewListenView Earnings Details
11/6/2014Q314($0.16)($0.15)$8.30 million$8.80 millionViewListenView Earnings Details
8/5/2014Q214($0.16)($0.19)$9.84 million$9.16 millionViewListenView Earnings Details
5/8/2014Q114($0.17)($0.20)$8.71 million$7.70 millionViewListenView Earnings Details
3/5/2014Q413($0.09)($0.13)$8.68 million$9.90 millionViewListenView Earnings Details
11/4/2013Q313($0.09)($0.12)$9.33 million$7.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.15)($0.13)$8.63 million$8.90 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.14)($0.21)$9.28 million$7.00 millionViewListenView Earnings Details
3/15/2013Q4 2012($0.17)($0.16)$9.87 million$9.50 millionViewListenView Earnings Details
11/8/2012Q312($0.16)($0.16)$9.98 million$8.50 millionViewN/AView Earnings Details
8/8/2012($0.28)($0.26)ViewN/AView Earnings Details
5/14/2012($0.14)($0.16)ViewN/AView Earnings Details
3/8/2012($0.36)($0.36)ViewN/AView Earnings Details
11/10/2011($0.55)($0.59)ViewN/AView Earnings Details
8/10/2011Q2 2011($4.16)($4.51)ViewN/AView Earnings Details
5/16/2011($0.50)($0.56)ViewN/AView Earnings Details
3/3/2011($0.62)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Zogenix (NASDAQ:ZGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($3.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.97)($0.77)($0.87)
Q2 20182($0.94)($0.85)($0.90)
Q3 20182($0.98)($0.74)($0.86)
Q4 20182($1.02)($0.98)($1.00)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Zogenix (NASDAQ:ZGNX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Zogenix (NASDAQ ZGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 73.47%
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)
Insider Trades by Quarter for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ ZGNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2017Bradley S. GalerEVPBuy1,346$36.59$49,250.14View SEC Filing  
12/11/2017Roger HawleyDirectorSell63,203$36.84$2,328,398.52105,575View SEC Filing  
12/8/2017Roger HawleyDirectorSell11,797$37.02$436,724.94105,575View SEC Filing  
10/3/2017Life Sciences Maste PerceptiveMajor ShareholderBuy300,000$37.50$11,250,000.00View SEC Filing  
9/29/2017Life Sciences Maste PerceptiveMajor ShareholderBuy222,055$32.83$7,290,065.65View SEC Filing  
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy175,653$14.45$2,538,185.85View SEC Filing  
3/16/2017Renee P TannenbaumDirectorBuy5,000$11.00$55,000.0010,000View SEC Filing  
12/15/2015Roger HawleyDirectorBuy10,000$13.74$137,400.001,404,447View SEC Filing  
6/13/2014Cam L GarnerDirectorBuy30,000$1.66$49,800.00View SEC Filing  
6/3/2014Ann D RhoadsCFOSell19,229$2.10$40,380.90View SEC Filing  
6/3/2014Roger HawleyCEOSell25,078$2.10$52,663.80View SEC Filing  
6/3/2014Stephen J FarrCOOSell20,900$2.10$43,890.00View SEC Filing  
11/20/2013Richard Scott ShivelyInsiderBuy67,000$2.79$186,930.0079,500View SEC Filing  
12/13/2012Cynthia Y RobinsonInsiderBuy50,000$1.17$58,500.00View SEC Filing  
12/12/2012Ann D RhoadsCFOBuy17,500$1.19$20,825.00View SEC Filing  
12/12/2012Cam L GarnerDirectorBuy70,000$1.21$84,700.00View SEC Filing  
12/11/2012Erle T MastDirectorBuy10,000$1.15$11,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zogenix (NASDAQ ZGNX) News Headlines

Source:
DateHeadline
Zogenix (ZGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowZogenix (ZGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:00 PM
BidaskClub Upgrades Zogenix (ZGNX) to "Buy"BidaskClub Upgrades Zogenix (ZGNX) to "Buy"
www.americanbankingnews.com - February 10 at 7:24 AM
Stock Traders Buy Large Volume of Call Options on Zogenix (ZGNX)Stock Traders Buy Large Volume of Call Options on Zogenix (ZGNX)
www.americanbankingnews.com - February 9 at 1:10 AM
Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceZogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:31 AM
BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008
www.reuters.com - February 6 at 4:01 PM
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome - GlobeNewswire (press release)Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome - GlobeNewswire (press release)
globenewswire.com - February 6 at 9:32 AM
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet SyndromeZogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
finance.yahoo.com - February 6 at 9:32 AM
Zogenix (ZGNX) Stock Rating Upgraded by ValuEngineZogenix (ZGNX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 6:22 AM
Zogenix, Inc. (ZGNX) Receives Average Recommendation of "Buy" from AnalystsZogenix, Inc. (ZGNX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 4 at 5:30 AM
BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet SyndromeBRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome
www.reuters.com - February 1 at 9:40 AM
Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet SyndromeZogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome
finance.yahoo.com - February 1 at 9:40 AM
Zogenix (ZGNX) Upgraded to "Hold" by Zacks Investment ResearchZogenix (ZGNX) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 27 at 1:46 PM
Zogenix Target of Unusually High Options Trading (ZGNX)Zogenix Target of Unusually High Options Trading (ZGNX)
www.americanbankingnews.com - January 22 at 1:28 AM
Zogenix (ZGNX) Downgraded by BidaskClubZogenix (ZGNX) Downgraded by BidaskClub
www.americanbankingnews.com - January 12 at 12:40 AM
Zogenix, Inc. (ZGNX) Given Consensus Recommendation of "Buy" by AnalystsZogenix, Inc. (ZGNX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 10 at 5:38 AM
Zogenix CEO explains company pivot from opioids to epilepsy drugsZogenix CEO explains company pivot from opioids to epilepsy drugs
www.bizjournals.com - January 4 at 4:23 PM
Commit To Purchase Zogenix At $23, Earn 19.6% Using OptionsCommit To Purchase Zogenix At $23, Earn 19.6% Using Options
www.nasdaq.com - December 30 at 10:14 AM
Ganaxalone Faces Stiff Competition from Other Drugs under DevelopmentGanaxalone Faces Stiff Competition from Other Drugs under Development
finance.yahoo.com - December 27 at 1:14 PM
-$1.01 EPS Expected for Zogenix, Inc. (ZGNX) This Quarter-$1.01 EPS Expected for Zogenix, Inc. (ZGNX) This Quarter
www.americanbankingnews.com - December 23 at 1:24 AM
BRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 MlnBRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 Mln
www.reuters.com - December 22 at 6:26 PM
Zogenix, Inc. is trading above its 50 day moving average : ZGNX-US : December 20, 2017Zogenix, Inc. is trading above its 50 day moving average : ZGNX-US : December 20, 2017
finance.yahoo.com - December 20 at 10:38 AM
Zogenix, Inc. (ZGNX) Receives Average Recommendation of "Buy" from BrokeragesZogenix, Inc. (ZGNX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 16 at 5:42 AM
Zogenix, Inc. (ZGNX) EVP Purchases $49,250.14 in StockZogenix, Inc. (ZGNX) EVP Purchases $49,250.14 in Stock
www.americanbankingnews.com - December 15 at 6:54 PM
Zogenix, Inc. (ZGNX) Director Sells $436,724.94 in StockZogenix, Inc. (ZGNX) Director Sells $436,724.94 in Stock
www.americanbankingnews.com - December 11 at 8:53 PM
Roger Hawley Sells 63,203 Shares of Zogenix, Inc. (ZGNX) StockRoger Hawley Sells 63,203 Shares of Zogenix, Inc. (ZGNX) Stock
www.americanbankingnews.com - December 11 at 8:50 PM
Zogenix (ZGNX) Earns Buy Rating from MizuhoZogenix (ZGNX) Earns Buy Rating from Mizuho
www.americanbankingnews.com - December 7 at 8:34 AM
Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : December 6, 2017Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : December 6, 2017
finance.yahoo.com - December 6 at 4:24 PM
Zogenix, Inc. breached its 50 day moving average in a Bearish Manner : ZGNX-US : December 5, 2017Zogenix, Inc. breached its 50 day moving average in a Bearish Manner : ZGNX-US : December 5, 2017
finance.yahoo.com - December 5 at 12:19 PM
Zogenix (ZGNX) Announces New Positive Efficacy, Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome at AESZogenix (ZGNX) Announces New Positive Efficacy, Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome at AES
www.streetinsider.com - December 4 at 4:21 PM
Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet SyndromeZogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
finance.yahoo.com - December 4 at 10:37 AM
Zogenix (ZGNX) Begins Phase 3 Trial for ZX008 in Lennox-Gastaut SyndromeZogenix (ZGNX) Begins Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
www.streetinsider.com - November 30 at 11:14 AM
Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut SyndromeZogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
finance.yahoo.com - November 29 at 10:41 AM
Zogenix to Participate in the Global Mizuho Investor Conference 2017Zogenix to Participate in the Global Mizuho Investor Conference 2017
feeds.benzinga.com - November 29 at 8:23 AM
Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4
finance.yahoo.com - November 28 at 11:38 AM
As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More UpsideAs Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside
www.msn.com - November 27 at 3:35 PM
JMP Securities Begins Coverage on Zogenix, Inc. (ZGNX)JMP Securities Begins Coverage on Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - November 27 at 8:36 AM
Zogenix (ZGNX) Announces New Data from Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at AESZogenix (ZGNX) Announces New Data from Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at AES
www.streetinsider.com - November 23 at 6:26 PM
Zogenix (ZGNX) Announces New Data from Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on ... - StreetInsider.comZogenix (ZGNX) Announces New Data from Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on ... - StreetInsider.com
www.streetinsider.com - November 23 at 8:26 AM
Zogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by BrokeragesZogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 21 at 5:56 AM
Zacks: Analysts Expect Zogenix, Inc. (ZGNX) Will Post Earnings of -$1.01 Per ShareZacks: Analysts Expect Zogenix, Inc. (ZGNX) Will Post Earnings of -$1.01 Per Share
www.americanbankingnews.com - November 16 at 5:30 PM
Zogenix to Present at Stifel 2017 Healthcare ConferenceZogenix to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 16 at 10:29 AM
FY2017 EPS Estimates for Zogenix, Inc. (ZGNX) Lowered by AnalystFY2017 EPS Estimates for Zogenix, Inc. (ZGNX) Lowered by Analyst
www.americanbankingnews.com - November 10 at 12:26 PM
FY2017 EPS Estimates for Zogenix, Inc. Decreased by Analyst (ZGNX)FY2017 EPS Estimates for Zogenix, Inc. Decreased by Analyst (ZGNX)
www.americanbankingnews.com - November 10 at 12:26 PM
Research Analysts Offer Predictions for Zogenix, Inc.s Q2 2018 Earnings (ZGNX)Research Analysts Offer Predictions for Zogenix, Inc.'s Q2 2018 Earnings (ZGNX)
www.americanbankingnews.com - November 9 at 12:34 PM
Edited Transcript of ZGNX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of ZGNX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 10:49 AM
Mizuho Reiterates Buy Rating for Zogenix, Inc. (ZGNX)Mizuho Reiterates Buy Rating for Zogenix, Inc. (ZGNX)
www.americanbankingnews.com - November 8 at 10:26 PM
Zogenixs (ZGNX) CEO Stephen Farr on Q3 2017 Results - Earnings Call TranscriptZogenix's (ZGNX) CEO Stephen Farr on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 2:25 AM
Zogenix reports 3Q lossZogenix reports 3Q loss
finance.yahoo.com - November 7 at 9:24 PM
Zogenix, Inc. to Host Earnings CallZogenix, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 4:19 PM
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsZogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 4:19 PM

SEC Filings

Zogenix (NASDAQ:ZGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zogenix (NASDAQ:ZGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zogenix (NASDAQ ZGNX) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.